Initiation, discontinuation, and restarting HIV pre-exposure prophylaxis: ongoing implementation strategies.
Journal
The lancet. HIV
ISSN: 2352-3018
Titre abrégé: Lancet HIV
Pays: Netherlands
ID NLM: 101645355
Informations de publication
Date de publication:
10 2020
10 2020
Historique:
received:
03
02
2020
revised:
09
04
2020
accepted:
05
05
2020
pubmed:
31
8
2020
medline:
21
10
2020
entrez:
31
8
2020
Statut:
ppublish
Résumé
When used appropriately, pre-exposure prophylaxis (PrEP) substantially reduces the risk of HIV acquisition. Early implementation outcomes often suggest poor PrEP adherence and persistence; however, this intervention is time-limited and the need for PrEP fluctuates as risk behaviours change. In this Viewpoint we examine the current guidelines and early programmatic outcomes after starting, stopping, and restarting PrEP, and we review the implications of PrEP in relation to HIV testing algorithms. Guidelines suggest to discontinue PrEP when a person is no longer at risk for HIV, but effectively implementing this strategy requires support tools to make the decision of stopping and restarting PrEP that considers the complex relationship between risk perceptions and risk behaviours. Safely discontinuing PrEP also requires greater understanding of the daily dosing duration that is needed to protect the person after their last HIV exposure. Additionally, clear strategies are needed to re-engage a person as their HIV exposure risk changes over time.
Identifiants
pubmed: 32861269
pii: S2352-3018(20)30203-4
doi: 10.1016/S2352-3018(20)30203-4
pmc: PMC7541752
mid: NIHMS1626795
pii:
doi:
Substances chimiques
Anti-HIV Agents
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
e721-e730Subventions
Organisme : World Health Organization
ID : 001
Pays : International
Organisme : NIAID NIH HHS
ID : P30 AI050410
Pays : United States
Organisme : NIAID NIH HHS
ID : U01 AI068619
Pays : United States
Informations de copyright
Copyright © 2020 Elsevier Ltd. All rights reserved.
Références
BMJ Open. 2019 Jun 27;9(6):e028768
pubmed: 31248931
Lancet HIV. 2016 Jul;3(7):e289-96
pubmed: 27365203
J Acquir Immune Defic Syndr. 2019 Dec 15;82(5):427-430
pubmed: 31714421
J Infect Dis. 2017 Aug 1;216(3):382-386
pubmed: 28666370
J Acquir Immune Defic Syndr. 2012 Aug 1;60(4):421-7
pubmed: 22487585
Lancet. 2013 Jun 15;381(9883):2083-90
pubmed: 23769234
N Engl J Med. 2015 Dec 3;373(23):2237-46
pubmed: 26624850
J Acquir Immune Defic Syndr. 2017 Jan 1;74(1):15-20
pubmed: 27552158
AIDS Behav. 2018 Nov;22(11):3645-3648
pubmed: 29728950
Lancet HIV. 2017 Nov;4(11):e522-e528
pubmed: 28919303
N Engl J Med. 2015 Feb 5;372(6):509-18
pubmed: 25651245
Clin Infect Dis. 2018 May 17;66(11):1712-1721
pubmed: 29420695
Clin Infect Dis. 2020 Jul 27;71(3):574-582
pubmed: 31499518
J Acquir Immune Defic Syndr. 2017 Dec 15;76(5):488-492
pubmed: 28961676
Clin Infect Dis. 2015 Nov 15;61(10):1601-3
pubmed: 26334052
Open Forum Infect Dis. 2019 Feb 26;6(4):ofz101
pubmed: 30949540
J Int AIDS Soc. 2019 Jul;22(7):e25359
pubmed: 31353814
JAMA. 2018 Jul 24;320(4):379-396
pubmed: 30043070
Lancet HIV. 2020 Jan;7(1):e38-e48
pubmed: 31813837
Sex Transm Dis. 2019 Apr;46(4):221-228
pubmed: 30870322
J Int AIDS Soc. 2016 Jun 13;19(1):20903
pubmed: 27302837
N Engl J Med. 2012 Aug 2;367(5):411-22
pubmed: 22784040
N Engl J Med. 2010 Dec 30;363(27):2587-99
pubmed: 21091279
AIDS Educ Prev. 2018 Oct;30(5):393-405
pubmed: 30332309
PLoS Med. 2008 Feb;5(2):e28
pubmed: 18254653
J Int AIDS Soc. 2014 Sep 08;17(3 Suppl 2):19152
pubmed: 25224613
AIDS Behav. 2016 Jul;20(7):1400-7
pubmed: 26538056
Lancet HIV. 2017 Sep;4(9):e402-e410
pubmed: 28747274
Cult Health Sex. 2016 Sep;18(9):1081-91
pubmed: 27093238
J Acquir Immune Defic Syndr. 2018 Jan 1;77(1):e8-e10
pubmed: 28961677
Lancet HIV. 2018 Nov;5(11):e629-e637
pubmed: 30343026
J Acquir Immune Defic Syndr. 2016 Dec 15;73(5):540-546
pubmed: 27851714
J Int AIDS Soc. 2019 Jul;22 Suppl 4:e25298
pubmed: 31328444
Clin Infect Dis. 2015 Mar 1;60(5):804-10
pubmed: 25409469
N Engl J Med. 2017 Feb 2;376(5):501-502
pubmed: 28146652
Clin Infect Dis. 2017 Mar 15;64(6):751-758
pubmed: 28034882
J Int AIDS Soc. 2019 Feb;22(2):e25252
pubmed: 30775846
J Int AIDS Soc. 2019 Feb;22(2):e25250
pubmed: 30768762
AIDS Behav. 2018 Apr;22(4):1096-1099
pubmed: 29243109
AIDS Behav. 2019 Oct;23(10):2730-2740
pubmed: 30953305
AIDS. 2017 Sep 10;31(14):2007-2016
pubmed: 28692542
JAMA Netw Open. 2019 Dec 2;2(12):e1917134
pubmed: 31825501
J Acquir Immune Defic Syndr. 2019 Aug 1;81(4):e104-e108
pubmed: 30985557
Clin Infect Dis. 2015 Jul 15;61(2):281-7
pubmed: 25870333
Clin Infect Dis. 2017 Sep 1;65(5):712-718
pubmed: 28505240
J Acquir Immune Defic Syndr. 2016 Mar 1;71(3):272-80
pubmed: 26428231
AIDS. 2019 Nov 15;33(14):2189-2195
pubmed: 31436610
AIDS Res Ther. 2006 Nov 28;3:29
pubmed: 17132170
J Acquir Immune Defic Syndr. 2018 Jun 1;78(2):e11-e13
pubmed: 29481487
J Int AIDS Soc. 2016 Jun 03;19(1):20777
pubmed: 27265490
J Acquir Immune Defic Syndr. 2017 Jul 1;75(3):271-279
pubmed: 28328548
N Engl J Med. 2012 Aug 2;367(5):399-410
pubmed: 22784037
Lancet HIV. 2017 Aug;4(8):e331-e340
pubmed: 28546090
Lancet HIV. 2017 Nov;4(11):e482-e483
pubmed: 29066095
JAMA Intern Med. 2016 Jan;176(1):75-84
pubmed: 26571482
BMC Public Health. 2017 Jul 21;18(1):42
pubmed: 28732496
Lancet HIV. 2018 Feb;5(2):e68-e78
pubmed: 28986029
J Acquir Immune Defic Syndr. 2018 Mar 1;77(3):272-278
pubmed: 29210835
HIV Med. 2019 Mar;20 Suppl 2:s2-s80
pubmed: 30869189
South Afr J HIV Med. 2016 Mar 15;17(1):455
pubmed: 29568613
AIDS. 2015 Jul 17;29(11):1277-85
pubmed: 26103095
J Acquir Immune Defic Syndr. 2013 Mar 1;62(3):339-47
pubmed: 23187945
AIDS Behav. 2018 Nov;22(11):3566-3575
pubmed: 29404756
Nat Commun. 2019 May 1;10(1):2005
pubmed: 31043606
PLoS Med. 2019 Sep 3;16(9):e1002885
pubmed: 31479452
JAMA. 2019 Apr 9;321(14):1380-1390
pubmed: 30964528
Cult Health Sex. 2008 Aug;10(6):563-72
pubmed: 18649195